Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies

Cancer Biology and Therapy

Volumn 9, Issue 9, 2010, Pages 678-684

  David, Kevin A ^a   Mongan, Nigel P ^b   Smith, Christopher ^a   Gudas, Lorraine J ^b   Nanus, David M ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ATRA; Cancer; Histone deacetylase inhibitors; Phase I trial; Valproic acid

Indexed keywords

RETINOIC ACID BINDING PROTEIN; RETINOIC ACID BINDING PROTEIN 2; RETINOIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; RETINOIC ACID; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE DEACETYLASE; VALPROIC ACID;

ADULT; AGED; AIRWAY OBSTRUCTION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLADDER TUMOR; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGUS TUMOR; FATIGUE; GENE EXPRESSION; HEADACHE; HOT FLUSH; HUMAN; KIDNEY TUMOR; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MOOD; NAUSEA AND VOMITING; NOCTURIA; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PROSTATE TUMOR; PROTEIN EXPRESSION; SARCOMA; SCORING SYSTEM; SIDE EFFECT; SKIN ALLERGY; SKIN TOXICITY; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; ABDOMINAL PAIN; ADENOCARCINOMA; ADVANCED CANCER; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONSTIPATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; GASTROESOPHAGEAL ADENOCARCINOMA; KIDNEY CARCINOMA; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; PARALYSIS; PROSTATE ADENOCARCINOMA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; CHEMISTRY; MIDDLE AGED; NEOPLASM; SALVAGE THERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TRETINOIN; VALPROIC ACID;

EID: 79952029974     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.9.11436     Document Type: Article

References (38)

1. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annual review of nutrition 2004; 24:201-21.
2. Hu L, Gudas LJ. Cyclic AMP analogs and retinoic acid influence the expression of retinoic acid receptor alpha, beta and gamma mRNAs in F9 teratocarcinoma cells. Mol Cell Biol 1990; 10:391-6.
3. Qiu H, Zhang W, El-Naggar AK, Lippman SM, Lin P, Lotan R, Xu XC. Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis. The American journal of pathology 1999; 155:1519-23.
4. Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 2000; 18:116-21. (Pubitemid 30036344)
5. Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F, et al. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res 1997; 57:4992-6. (Pubitemid 27498106)
6. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, et al. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 1997; 89:624-9. (Pubitemid 27200493)
7. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-72.
8. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105:3019-25. (Pubitemid 40504316)
9. Guo X, Gudas LJ. Metabolism of all-trans-retinol in normal human cell strains and squamous cell carcinoma (SCC) lines from the oral cavity and skin: reduced esterification of retinol in SCC lines. Cancer Res 1998; 58:166-76. (Pubitemid 28027732)
10. Chen AC, Guo X, Derguini F, Gudas LJ. Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol. Cancer Res 1997; 57:4642-51. (Pubitemid 27441073)
11. Guo X, Nanus DM, Ruiz A, Rando RR, Bok D, Gudas LJ. Reduced levels of retinyl esters and vitamin A in human renal cancers. Cancer Res 2001; 61:2774-81. (Pubitemid 32685868)
12. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10:839-64.
13. Lippman SM, Meyskens FL Jr. Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmacol Ther 1989; 40:107-22.
14. Nastruzzi C, Walde P, Menegatti E, Gambari R. Liposome-associated retinoic acid. Increased in vitro antiproliferative effects on neoplastic cells. FEBS Lett 1990; 259:293-6.
15. Parthasarathy R, Sacks PG, Harris D, Brock H, Mehta K. Interaction of liposome-associated all-transretinoic acid with squamous carcinoma cells. Cancer Chemother Pharmacol 1994; 34:527-34. (Pubitemid 24306054)
16. Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F, Ford RJ Jr. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 1997; 8:1071-82. (Pubitemid 27433295)
17. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005; 68:917-32. (Pubitemid 41345783)
18. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001; 48:17-9.
19. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13:2318-22.
20. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003; 22:3411-20.
21. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65:520-7.
22. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45:737-44.
23. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20:6969-78.
24. Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005; 25:383-97.
25. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007; 97:177-82.
26. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006; 66:8903-11.
27. Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005; 19:1161-8.
28. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005; 84:61-6.
29. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104:1266-9.
30. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106:112-9.
31. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 2005; 11:3558-66.
32. Common Toxicity Criteria, version 2.0. Cancer Therapy Evaluation Program 1998.
33. Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, et al. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 2007; 30:655-62.
34. Guel H, Wassmann B, Romanski A. Effect of the histone deacetylase inhibitor valproic acid in combination with all-trans retinoic acid on normal and malignant hematopiesis. Blood 2003; 102:626.
35. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61:2-7.
36. Raffoux E, Chaibi P, Dombret H, Degos L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005; 90:986-8.
37. Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008; 31:629-33.
38. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110:2302-8.